fluvoxamine
Selected indexed studies
- Fluvoxamine for symptomatic outpatients with COVID-19. (CMAJ, 2022) [PMID:35045990]
- [Fluvoxamine in the treatment of anxiety-depressive spectrum disorders]. (Zh Nevrol Psikhiatr Im S S Korsakova, 2024) [PMID:39072574]
- Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials. (J Clin Psychopharmacol, 2020) [PMID:32618683]
_Worker-drafted node — pending editorial review._
Connections
fluvoxamine is a side effect of
Sources
- Fluvoxamine for symptomatic outpatients with COVID-19. (2022) pubmed
- [Fluvoxamine in the treatment of anxiety-depressive spectrum disorders]. (2024) pubmed
- Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials. (2020) pubmed
- Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. (2021) pubmed
- Lack of Benefit of Fluvoxamine for COVID-19. (2023) pubmed
- Fluvoxamine for the treatment of COVID-19. (2022) pubmed
- Fluvoxamine for the treatment of COVID-19. (2022) pubmed
- Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis. (2022) pubmed
- Fluvoxamine: an antidepressant for the elderly? (1991) pubmed
- Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes. (2024) pubmed